Form 4: Ligand Pharmaceuticals Director Jason Haas Acquires Shares and Stock Options

Director Jason Haas acquired Ligand Pharmaceuticals stock and stock options on June 14, 2024, according to a Form 4 filing.

Summary

• On June 14, 2024, Jason Haas, a director of Ligand Pharmaceuticals, acquired 1,252 shares of common stock in the form of restricted stock units (RSUs).
• These RSUs were granted by the Board of Directors at their annual meeting and represent a contingent right to receive one share of Ligand's common stock each.
• Haas also acquired 5,444 non-qualified stock options with an exercise price of $80.06.
• These options were also granted at the annual meeting and are exercisable from June 14, 2024, until June 14, 2034.
• Both the RSUs and stock options fully vest on the earlier of the next annual meeting of stockholders or the first anniversary of the grant date.
• Following these transactions, Haas beneficially owns 5,397 shares of common stock and 5,444 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares and options by a director suggests confidence, but it's a routine transaction.

Positives

• The acquisition of shares and stock options by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The vesting of the RSUs and stock options is contingent upon the earlier of the next annual meeting of the company stockholders or the first anniversary of the grant date.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge sentiment and potential future performance.

Stakeholder Impact

• The acquisition of shares by a director may have a slightly positive impact on shareholder sentiment.

Key Dates